Haemonetics Corporation
HealthcareNYSE:HAE · New York Stock Exchange
-$1.64 today
Vol 1.05M · Avg 0.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.2%
avg 8.3%
ROIC
8.7%
avg 4.8%
ROA
4.1%
avg 3.3%
Analysis
ROE is currently the strongest return metric at 12.2% versus its period average of 8.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher A. Simon | Chief Executive Officer, President & Director | $2.98M | — | 62 | $40,987.00 | 0.09% |
James C. D'Arecca | Chief Financial Officer, Executive Vice President & Financial Officer | $1.28M | — | 55 | $25,132.00 | 0.06% |
Michelle L. Basil | Executive Vice President, General Counsel & Secretary | $922,827.00 | — | 53 | $40,405.00 | 0.09% |
Roy Galvin | Executive Vice President & Chief Commercial Officer | $909,621.00 | — | 56 | $12,347.00 | 0.03% |
Frank W. Chan | Executive Vice President & Chief Operating Officer | — | — | 56 | $5,401.00 | 0.01% |
Rajeev Varma | Senior Vice President of Strategy & Corporate Development | — | — | — | — | — |
Farris Maryanne Maunsell | Vice President, Chief Accounting Officer & Principal Accounting Officer | — | — | 50 | $6,242.00 | 0.01% |
Laurie A. Miller | Senior Vice President & Chief Human Resources Officer | — | — | 52 | $40,987.00 | 0.09% |
Olga Vlasova | Senior Manager of Investor Relations | — | — | — | — | — |
Jan Hartmann | Senior Vice President & Chief Medical Officer | — | — | — | — | — |
David J. Wilson | President of Plasma Business Unit | — | — | 58 | $16,867.00 | 0.04% |
David Trenk | Manager of Investor Relations | — | — | — | $16,867.00 | 0.04% |
Olga Guyette | Senior Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$98,784.00
Sells
0
$0.00
Net Sentiment
+$98,784.00
Net buying
Most Active
KROLL MARK W
1 transactions
Analysis
Insiders reported 1 buys worth $98,784.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $98,784.00. KROLL MARK W was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +0.6% | +4.4% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +0.6% over three years. Forward estimates point to Revenue at +4.4% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
Warby Parker Inc.
NYSE:WRBY
$3.25B
Integer Holdings Corporation
NYSE:ITGR
$3.09B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Premier, Inc.
PINC
$2.34B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.10B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
Who manages HAE?
Haemonetics Corporation (HAE) lists 13 active executives. The top listed executive is Christopher A. Simon, Chief Executive Officer, President & Director.
Are HAE insiders buying or selling?
Recent insider activity shows net selling of $22.65M.
Explore More
Continue the stock analysis
Jump to another research area for this company.